Welcome!

News Feed Item

Spinal Stenosis Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spinal Stenosis Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280947/Spinal-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

Spinal Stenosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spinal Stenosis Global Clinical Trials Review, H2, 2014" provides data on the Spinal Stenosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spinal Stenosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spinal Stenosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Spinal Stenosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Spinal Stenosis to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Spinal Stenosis to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Spinal Stenosis 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Spinal Stenosis Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Sucampo Pharmaceuticals, Inc. 31
Clinical Trial Overview of Sucampo Pharmaceuticals, Inc. 31
Mesoblast Limited 32
Clinical Trial Overview of Mesoblast Limited 32
Zimmer Holdings, Inc. 33
Clinical Trial Overview of Zimmer Holdings, Inc. 33
United Therapeutics Corporation 34
Clinical Trial Overview of United Therapeutics Corporation 34
Nissan Chemical Industries, Ltd. 35
Clinical Trial Overview of Nissan Chemical Industries, Ltd. 35
LTT Bio-Pharma Co., Ltd. 36
Clinical Trial Overview of LTT Bio-Pharma Co., Ltd. 36
KT&G Corporation 37
Clinical Trial Overview of KT&G Corporation 37
Kaken Pharmaceutical Co., Ltd. 38
Clinical Trial Overview of Kaken Pharmaceutical Co., Ltd. 38
Biomet, Inc. 39
Clinical Trial Overview of Biomet, Inc. 39
Clinical Trial Overview of Top Institutes / Government 40
Seoul National University Hospital 40
Clinical Trial Overview of Seoul National University Hospital 40
Keio University 41
Clinical Trial Overview of Keio University 41
Hamamatsu University School of Medicine 42
Clinical Trial Overview of Hamamatsu University School of Medicine 42
University of Pittsburgh 43
Clinical Trial Overview of University of Pittsburgh 43
Vanderbilt University 44
Clinical Trial Overview of Vanderbilt University 44
Leiden University Medical Center 45
Clinical Trial Overview of Leiden University Medical Center 45
Yonsei University 46
Clinical Trial Overview of Yonsei University 46
Dartmouth-Hitchcock Medical Center 47
Clinical Trial Overview of Dartmouth-Hitchcock Medical Center 47
Emory University 48
Clinical Trial Overview of Emory University 48
Federal University of Sao Paulo 49
Clinical Trial Overview of Federal University of Sao Paulo 49
Five Key Clinical Profiles 50
Appendix 68
Abbreviations 68
Definitions 68
Research Methodology 69
Secondary Research 69
About GlobalData 70
Contact Us 70
Disclaimer 70
Source 70

List of Tables

Spinal Stenosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Spinal Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Spinal Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Spinal Stenosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Spinal Stenosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Spinal Stenosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Stenosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Spinal Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Stenosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Spinal Stenosis Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Spinal Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Spinal Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Spinal Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sucampo Pharmaceuticals, Inc., 2014* 31
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Mesoblast Limited, 2014* 32
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Zimmer Holdings, Inc., 2014* 33
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by United Therapeutics Corporation, 2014* 34
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Nissan Chemical Industries, Ltd., 2014* 35
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by LTT Bio-Pharma Co., Ltd., 2014* 36
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by KT&G Corporation, 2014* 37
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Kaken Pharmaceutical Co., Ltd., 2014* 38
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Biomet, Inc., 2014* 39
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Hospital, 2014* 40
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Keio University, 2014* 41
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamamatsu University School of Medicine, 2014* 42
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 43
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Vanderbilt University, 2014* 44
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2014* 45
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Yonsei University, 2014* 46
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Dartmouth-Hitchcock Medical Center, 2014* 47
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 48
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Federal University of Sao Paulo, 2014* 49

List of Figures

Spinal Stenosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Spinal Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Spinal Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Spinal Stenosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Stenosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Spinal Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Spinal Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Spinal Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 69


To order this report: Spinal Stenosis Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280947/Spinal-Stenosis-Global-Clinical-Trials-Review-H2-2014.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
For financial firms, the cloud is going to increasingly become a crucial part of dealing with customers over the next five years and beyond, particularly with the growing use and acceptance of virtual currencies. There are new data storage paradigms on the horizon that will deliver secure solutions for storing and moving sensitive financial data around the world without touching terrestrial networks. In his session at 20th Cloud Expo, Cliff Beek, President of Cloud Constellation Corporation, w...
In order to meet the rapidly changing demands of today’s customers, companies are continually forced to redefine their business strategies in order to meet these needs, stay relevant and continue to see profitable growth. IoT deployment and development is integral in this transformation, and today businesses are increasingly seeing the value of investing their resources into IoT deployments. These technologies are able increase ROI through projects such as connecting supply chains or enabling sm...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, will motivate why realizing the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is the best cloud operating system for enterprises today, providing rapid development and deployment of applications that can take advantage of the rich catalog of Watson services to help drive insigh...
IBM helps FinTechs and financial services companies build and monetize cognitive-enabled financial services apps quickly and at scale. Hosted on IBM Bluemix, IBM’s platform builds in customer insights, regulatory compliance analytics and security to help reduce development time and testing. In his session at 20th Cloud Expo, Tom Eck, Industry Platforms CTO at IBM Cloud, will discuss how these tools simplify the time-consuming tasks of selection, mapping and data integration, allowing developers ...
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
As enterprise cloud becomes the norm, businesses and government programs must address compounded regulatory compliance related to data privacy and information protection. The most recent, Controlled Unclassified Information and the EU’s GDPR have board level implications and companies still struggle with demonstrating due diligence. Developers and DevOps leaders, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by in...
SYS-CON Events announced today that EARP Integration will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. EARP Integration is a passionate software house. Since its inception in 2009 the company successfully delivers smart solutions for cities and factories that start their digital transformation. EARP provides bespoke solutions like, for example, advanced enterprise portals, business intelligence systems an...
SYS-CON Events announced today that Outscale, a global pure play Infrastructure as a Service provider and strategic partner of Dassault Systèmes, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2010, Outscale simplifies infrastructure complexities and boosts the business agility of its customers. Outscale delivers a secure, reliable and industrial strength solution for its customers, which in...
SYS-CON Events announced today that Progress, a global leader in application development, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Enterprises today are rapidly adopting the cloud, while continuing to retain business-critical/sensitive data inside the firewall. This is creating two separate data silos – one inside the firewall and the other outside the firewall. Cloud ISVs oft...
As cloud adoption continues to transform business, today's global enterprises are challenged with managing a growing amount of information living outside of the data center. The rapid adoption of IoT and increasingly mobile workforce are exacerbating the problem. Ensuring secure data sharing and efficient backup poses capacity and bandwidth considerations as well as policy and regulatory compliance issues.
The 21st International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo Silicon Valley Call for Papers is now open.